期刊文献+

不同方法检测淋巴瘤病理标本EB病毒的比较

Comparison in Examining EB Virus Among Iymphoma Cases with The Use of Different Methods
暂未订购
导出
摘要 目的 :探讨用不同方法检测淋巴瘤标本中EB病毒LMP 1的表达率以选择一种敏感、可靠的检测手段。方法 :运用SP法、CSA法检测EB病毒LMP 1在Raji细胞株细胞学涂片、12 3例淋巴瘤 (其中 10 4例NHL ,19例HL)切片中的表达 ,部分病例结合PCR加以验证。结果 :(1)细胞学涂片SP阳性细胞率为 70±10 % ,CSA法 10 0 %阳性。 (2 )HL中 ,SP法检测LMP 1阳性率为 6 / 19(32 % ) ,CSA法阳性率 8/ 19(4 2 % ) ,PCR阳性率为 11/ 19(5 8% )。 (3)非霍奇金淋巴瘤 (NHL)中SP法阳性率为 3/ 10 4 (其中B NHL 1/ 79,1 2 6 % ,T NHL2 / 2 5 ,8% )。CSA法阳性率为 9/ 10 4 ,其中B NHL4 / 79(5 % ) ,T NHL 5 / 2 5 (2 0 % ) ,ITCL达 2 / 10 (2 0 % )。结论 :SP法在检测低丰度抗原时漏检率较高 ,CSA法为一种较敏感、可靠的检测手段 ,结合PCR方法可有效检测低丰度抗原。 Objective:To choose a sensitive and reliable way of examination through using different methods to check the performance rate of LMP-1 in the lymphoma cases.Methods:using SP method,CSA method to examine the performance of LMP-1 on the Raji cell smear and the slides of 123 lymphoma cases (104/123 are NHL,19/123 are HL).Some cases used the PCR method too.Results:(1)the cell rate of SP Positive on the cytology smear is 70±10%;(2)Among HL,LMP-1 Positive rates examined by SP method is 6/19(32%),by CSA method is 8/19(42%),by PCR method is 11/19(58%);(3)Among NHL,Positive rate examined by SP method is 3/104(B-NHL 1/79,1.26%;T-NHL 2/25,8%);by CSA method 9/104(B-NHL 4/79,5%;T-NHL 5/25,20%,ITCL 2/10,20%).Conclusion:SP method has a higher mission in checking low-density antigen,whiole,the CSA method is a more sensitive and reliable method,which can check them effectively with the help of the PCR method.
作者 冯晓文 周韧
出处 《上海生物医学工程》 2004年第1期3-6,共4页 Shanghai Journal of Biomedical Engineering
  • 相关文献

参考文献6

二级参考文献30

  • 1张开.TUNEL法──细胞凋亡的组织化学鉴定法[J].日本医学介绍,1995,16(10):469-469. 被引量:11
  • 2宝福凯.bcl-2基因家族对细胞凋亡的调节[J].生理科学进展,1996,27(1):67-69. 被引量:8
  • 3刘卫平,Joostvan Gorp,李甘地,刘永惠,李俸媛,万红,Roel A de Weger.中线恶网中的EB病毒感染[J].中华肿瘤杂志,1997,19(1):49-52. 被引量:27
  • 4[1]Zur Hansen H,Schulte-Holthansen H, Klein G et al. EBV-DNA in Burkitt's tumor and anaplastic carcinoma of the nasopharynx. Nature, 1970;228:1056~8
  • 5[2]Kobayashi I, Shima K, Saito I et al. Prevalence of Epstein-Barr virus in oral squamous cell carcinoma. J Pathol, 1999;189: 34~9
  • 6[3]Morente MM, Piris MA, Abraira V et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1expression. Blood, 1997;90:2429~36
  • 7[4]Miller WE, Earp HS, Raabb-Traub N. The Epstein-Barr virus latent membrane protein1 induces expression of the epidermal growth factor receptor. J Virol, 1995;69:4390~8
  • 8[5]Kanavaros P, Jiwa M, Valk P et al. Expression of Epstein-Barr virus latent gene products and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency. Hum Pathol, 1993;24:725~9
  • 9[6]Moss DJ, Misko IS, Burrows SR et al. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature, 1988;331:719~21
  • 10[7]Yoshiyama H, Imai S, Shimizu N et al. Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21. J Virol, 1997;71:5688~91

共引文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部